Open-label, Single-dose, Randomized, Two-way Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of SCP-111 (Furosemide) vs Intravenous Injection of Furosemide in Healthy Volunteers
Latest Information Update: 21 May 2025
At a glance
- Drugs Furosemide (Primary) ; Furosemide
- Indications Heart failure
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors scPharmaceuticals
Most Recent Events
- 14 May 2025 According to scPharmaceuticals media release, company is targeting sNDA submission in Q3 2025.
- 12 Aug 2024 According to scPharmaceuticals media release, company plans to submit the full data set from this study for future presentation at a medical meeting or publication.
- 12 Aug 2024 Results presented in the scPharmaceuticals Media Release.